Main Industry
Health Care
Main Product/Service
1. Safety Syringes
2. Printing Solutions
2. Printing Solutions
Founded Year
2018
Unified Business No.
69755925
Status
Active
Number of Employees
0
Total Paid-in
Capital
400,000,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Since its inception in 2018, SMAS Technology Co., Ltd. has specialized in the printing of glucose test strips. Driven by a commitment to excellence, we continuously refine our processes to deliver products that meet the highest standards of stability and consistency, exceeding even the most stringent customer requirements.
Our products serve diverse industries, including RFID, electronic component printing, industrial control systems, nameplates, automotive panels, biosensor test strips, EMS (Electrical Muscle Stimulation), ECG, and other specialized printing applications. By combining cutting-edge technology with innovative craftsmanship, SMAS provides customers with precise, reliable, and efficient printing solutions.
In 2022,SMAS became a proud subsidiary of the Yao Sheng Group. That same year, we demonstrated our R&D strength by securing a patent for safety syringes and investing strategically in new ventures. To support our expansion and commitment to sustainability, we relocated to a state-of-the-art manufacturing facility in Daxi. This modern plant, spanning over 1,000 square meters and equipped with four advanced production lines, is dedicated to establishing a comprehensive safety syringe production chain. As Taiwan’s only manufacturer equipped with Japanese tri-bevel needle grinding technology, we continue to push the boundaries of innovation, enhancing our production processes and planning for fully automated syringe assembly lines. Our goal is to provide a complete MIT (Made in Taiwan) solution for safe syringe development, from R&D to production, ensuring the highest standards of safety for healthcare professionals.
Our high-safety syringes are designed with medical personnel in mind, prioritizing user experience and safety. These products significantly reduce the risks of cross-infection and lower medical waste disposal costs, reflecting our commitment to advancing global healthcare.
At SMAS, quality is more than a priority—it’s our guiding principle. We have achieved several authoritative certifications, including ISO13485, QMS, and TFDA, supported by a rigorous quality management system. By leveraging cutting-edge equipment, advanced techniques, and a team of industry-leading professionals, we deliver superior products and forge strong, win-win partnerships with our clients.
Looking ahead, SMAS remains dedicated to strengthening its roots in Taiwan while expanding into international markets. Building on our expertise in medical devices, we are actively exploring opportunities in smart energy and energy conservation sectors. Through technological innovation and cross-disciplinary collaboration, we aim to drive societal progress and contribute to a sustainable future.
Our products serve diverse industries, including RFID, electronic component printing, industrial control systems, nameplates, automotive panels, biosensor test strips, EMS (Electrical Muscle Stimulation), ECG, and other specialized printing applications. By combining cutting-edge technology with innovative craftsmanship, SMAS provides customers with precise, reliable, and efficient printing solutions.
In 2022,SMAS became a proud subsidiary of the Yao Sheng Group. That same year, we demonstrated our R&D strength by securing a patent for safety syringes and investing strategically in new ventures. To support our expansion and commitment to sustainability, we relocated to a state-of-the-art manufacturing facility in Daxi. This modern plant, spanning over 1,000 square meters and equipped with four advanced production lines, is dedicated to establishing a comprehensive safety syringe production chain. As Taiwan’s only manufacturer equipped with Japanese tri-bevel needle grinding technology, we continue to push the boundaries of innovation, enhancing our production processes and planning for fully automated syringe assembly lines. Our goal is to provide a complete MIT (Made in Taiwan) solution for safe syringe development, from R&D to production, ensuring the highest standards of safety for healthcare professionals.
Our high-safety syringes are designed with medical personnel in mind, prioritizing user experience and safety. These products significantly reduce the risks of cross-infection and lower medical waste disposal costs, reflecting our commitment to advancing global healthcare.
At SMAS, quality is more than a priority—it’s our guiding principle. We have achieved several authoritative certifications, including ISO13485, QMS, and TFDA, supported by a rigorous quality management system. By leveraging cutting-edge equipment, advanced techniques, and a team of industry-leading professionals, we deliver superior products and forge strong, win-win partnerships with our clients.
Looking ahead, SMAS remains dedicated to strengthening its roots in Taiwan while expanding into international markets. Building on our expertise in medical devices, we are actively exploring opportunities in smart energy and energy conservation sectors. Through technological innovation and cross-disciplinary collaboration, we aim to drive societal progress and contribute to a sustainable future.
